Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Fish and Richardson
Merck
Deloitte
QuintilesIMS
Daiichi Sankyo
Johnson and Johnson
UBS
Accenture

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,992,110

« Back to Dashboard

Which drugs does patent 6,992,110 protect, and when does it expire?

Patent 6,992,110 protects SAVELLA and is included in one NDA.

This patent has fourteen patent family members in nine countries.
Summary for Patent: 6,992,110
Title:Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
Abstract:The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
Inventor(s): Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Application Number:10/623,378
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 6,992,110

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF FIBROMYALGIA (FM) ➤ Sign Up
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF FIBROMYALGIA (FM) ➤ Sign Up
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-003 Jan 14, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up MANAGEMENT OF FIBROMYALGIA (FM) ➤ Sign Up
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 AB RX Yes No ➤ Sign Up ➤ Sign Up MANAGEMENT OF FIBROMYALGIA (FM) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,992,110

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,820,643 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Sign Up
7,888,342 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Sign Up
6,602,911 Methods of treating fibromyalgia ➤ Sign Up
7,915,246 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKesson
Moodys
Medtronic
McKinsey
Citi
Baxter
Federal Trade Commission
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.